PPARgamma-independent antitumor effects of thiazolidinediones.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Letters

• Publication date

  2009-04-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2008.08.008PMID 18790559PMCID PMC2712818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Novel Mechanism by Which Thiazolidinediones Facilitate the Proteasomal Degradation of Cyclin D1 in Cancer Cells*

  2008cited by this paper
• Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

  2008cited by this paper
• Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism.

  2007cited by this paper
• Thiazolidinediones Modulate the Expression of β-Catenin and Other Cell-Cycle Regulatory Proteins by Targeting the F-Box Proteins of Skp1-Cul1-F-box Protein E3 Ubiquitin Ligase Independently of Peroxisome Proliferator-Activated Receptor γ

  2007cited by this paper
• Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism

  2007cited by this paper
• Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.

  2007cited by this paper
• Ubiquitin ligases: cell-cycle control and cancer

  2006cited by this paper
• Peroxisome Proliferator-Activated Receptor γ-Independent Repression of Prostate-Specific Antigen Expression by Thiazolidinediones in Prostate Cancer Cells

  2006cited by this paper
• Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.

  2006cited by this paper
• Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin

  2006cited by this paper
• Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.

  2006cited by this paper
• Development of small-molecule cyclin D1-ablative agents.

  2006cited by this paper
• Regulation of the cell cycle by SCF-type ubiquitin ligases.

  2005cited by this paper
• Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells

  2005cited by this paper
• Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.

  2005cited by this paper
• Sp transcription factor family and its role in cancer.

  2005cited by this paper
• Troglitazone, a PPAR-γ activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-α

  2005cited by this paper
• Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.

  2005cited by this paper
• The SCF ubiquitin ligase: insights into a molecular machine

  2004cited by this paper
• Cell cycle, proteolysis and cancer.

  2004cited by this paper
• Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway.

  2004cited by this paper
• Approaches to understanding the importance and clinical implications of peroxisome proliferator‐activated receptor gamma (PPARγ) signaling in prostate cancer

  2004cited by this paper
• Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.

  2004cited by this paper
• Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes.

  2004cited by this paper
• Peroxisome Proliferator-activated Receptor γ Activation Can Regulate β-Catenin Levels via a Proteasome-mediated and Adenomatous Polyposis Coli-independent Pathway*

  2004cited by this paper
• Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists

  2004cited by this paper
• Regulating the Balance between Peroxisome Proliferator-activated Receptor γ and β-Catenin Signaling during Adipogenesis

  2004cited by this paper
• Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells.

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma and cancers.

  2003cited by this paper
• Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.

  2003cited by this paper
• Peroxisome Proliferator-activated Receptor γ Agonists Induce Proteasome-dependent Degradation of Cyclin D1 and Estrogen Receptor α in MCF-7 Breast Cancer Cells

  2003cited by this paper
• Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.

  2003cited by this paper
• Peroxisome proliferator-activated receptor γ and cancers

  2003cited by this paper
• Troglitazone induces p27Kip1‐associated cell‐cycle arrest through down‐regulating Skp2 in human hepatoma cells

  2003cited by this paper
• Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis.

  2003cited by this paper
• Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells.

  2003cited by this paper
• An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis*

  2002cited by this paper
• Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.

  2002cited by this paper
• Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.

  2001cited by this paper
• Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells.

  2001cited by this paper
• Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.

  2001cited by this paper
• Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation.

  2001cited by this paper
• PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth.

  2001cited by this paper
• Inhibition of Cellular Proliferation through IκB Kinase-Independent and Peroxisome Proliferator-Activated Receptor γ-Dependent Repression of Cyclin D1

  2001cited by this paper
• Target Genes of Peroxisome Proliferator-activated Receptor γ in Colorectal Cancer Cells*

  2001cited by this paper
• PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth*

  2001cited by this paper
• Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

  2000cited by this paper
• Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells.

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

  2000cited by this paper
• Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.

  2000cited by this paper
• Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

  1999cited by this paper
• Thiazolidinediones: a new class of antidiabetic drugs

  1999cited by this paper

• Development and validation of a prognosis model for low-grade gliomas based on metabolic gene risk scoring and immune microenvironment interaction.

  2026cites this paper
• Medications to reduce breast cancer risk: a network meta-analysis of randomized controlled trials

  2025cites this paper
• Design, Synthesis, Molecular Docking, Dynamics Simulation, and Biological Evaluation of Novel Thiazolidinedione Derivatives Against Breast Cancer with Apoptosis-Inducing Activity

  2025cites this paper
• Therapeutic Potential of Anti‐Diabetes Drugs and Anti‐Dyslipidemia Drugs to Mitigate Head and Neck Cancer Risk in Metabolic Syndrome

  2025cites this paper
• PPAR-γ in Melanoma and Immune Cells: Insights into Disease Pathogenesis and Therapeutic Implications

  2025influential citation
• Cross-talk between cancer and diabetes: Exploring shared molecular pathways in cellular metabolism and signaling.

  2025cites this paper
• Design, synthesis and mechanistic study of N-4-Piperazinyl Butyryl Thiazolidinedione derivatives of ciprofloxacin with Anticancer Activity via Topoisomerase I/II inhibition

  2024cites this paper
• Green synthesis, in silico modeling, and biological evaluation of N-substituted (Z)-5-arylidene imidazolidine/thiazolidine-2,4-dione/4-thione derivatives catalyzed by Bu SO3H core–shell nanostructures

  2024cites this paper
• Design and synthesis of novel chloropyridazine hybrids as promising anticancer agents acting by apoptosis induction and PARP-1 inhibition through a molecular hybridization strategy.

  2024cites this paper
• TorS ‐ Reframing a rational for type 2 diabetes treatment

  2023cites this paper
• Succinate metabolism: a promising therapeutic target for inflammation, ischemia/reperfusion injury and cancer

  2023cites this paper
• The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy

  2023cites this paper
• Pyrrolidinedione-thiazolidinone hybrid molecules with potent cytotoxic effect in squamous cell carcinoma SCC-15 cells.

  2023cites this paper
• PPAR Ligands Induce Antiviral Effects Targeting Perturbed Lipid Metabolism during SARS-CoV-2, HCV, and HCMV Infection

  2022cites this paper
• 4,5-diazafenylfluorene-rhodanine conjugates promote anoikis in A375 cells via inhibiting PPAR-γ expression

  2022cites this paper
• Antifungal Thiazolidines: Synthesis and Biological Evaluation of Mycosidine Congeners

  2022cites this paper
• Diabetes mellitus and multiple myeloma; common features of two distinct entities

  2022cites this paper
• PPAR-γ Modulators as Current and Potential Cancer Treatments

  2021cites this paper
• Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery.

  2021cites this paper
• PPARγ and Diabetes: Beyond the Genome and Towards Personalized Medicine

  2021cites this paper
• Lipid metabolism part I

  2021cites this paper
• Lipid metabolism part II

  2021cites this paper
• The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma

  2020cites this paper
• Antidiabetic Medications and the Risk of Prostate Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis.

  2020cites this paper
• Novel insights into adiponectin action in breast cancer: Evidence of its mechanistic effects mediated by ERα expression

  2020cites this paper
• The Emerging Role of Adiponectin in Female Malignancies

  2019cites this paper
• PPARγ Agonists in Combination Cancer Therapies.

  2019cites this paper
• Thiazolidine-2,4-dione in benzoylation reaction

  2019cites this paper
• Anticancer properties of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one

  2019cites this paper
• Thiazolidinedione therapy and breast cancer risk in diabetic women: A systematic review and meta‐analysis

  2018cites this paper
• Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARγ‐independent pathway

  2018cites this paper
• Troglitazone inhibits the migration and invasion of PC-3 human prostate cancer cells by upregulating E-cadherin and glutathione peroxidase 3.

  2018cites this paper
• A Sterol from Soft Coral Induces Apoptosis and Autophagy in MCF-7 Breast Cancer Cells

  2018cites this paper
• High expression of fibroblast growth factor-21 in liposarcoma patients indicated better prognosis and less recurrence.

  2018cites this paper
• In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer

  2017cites this paper
• CCL2 is Modulated by Cytokines and PPAR-γ in Anaplastic Thyroid Cancer.

  2017cites this paper
• New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias.

  2017cites this paper
• Novel 2,4- thiazolidinediones: Synthesis, in vitro cytotoxic activity, and mechanistic investigation.

  2017cites this paper
• Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.

  2016cites this paper
• Different molecular signaling sustaining adiponectin action in breast cancer.

  2016cites this paper
• Diabetes and Cancer: a Review of Current Knowledge.

  2016cites this paper
• Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism

  2016cites this paper
• PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity

  2016cites this paper
• (5Z)-3-(2-Oxoprop­yl)-5-(3,4,5-tri­meth­oxy­benzyl­idene)-1,3-thia­zol­idine-2,4-dione

  2016cites this paper
• Troglitazone Stimulates Cancer Cell Uptake of 18F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction

  2016cites this paper
• Evolving role of adiponectin in cancer-controversies and update

  2016cites this paper
• Avaliação do perfil de citocinas e quimiocinas em pacientes com esclerose sistêmica: correlação com manifestações clínicas e com resposta ao tratamento

  2016cites this paper
• Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions

  2016cites this paper
• Various peroxisome proliferator‐activated receptor (PPAR)‐γ agonists differently induce differentiation of cultured human keratinocytes

  2015cites this paper
• Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor

  2015cites this paper
• PPARγ‐inactive Δ2‐troglitazone independently triggers ER stress and apoptosis in breast cancer cells

  2015cites this paper
• Cancer gene therapy: Prospects of using human sodium iodide symporter gene in non-thyroidal cancer

  2015cites this paper
• Nuclear actions of insulin-like growth factor binding protein-3.

  2015cites this paper
• Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials

  2014cites this paper
• PPARγ ligand ciglitazone inhibits TNFα-induced ICAM-1 in human airway smooth muscle cells

  2014cites this paper
• Minireview: Challenges and opportunities in development of PPAR agonists.

  2014cites this paper
• A new dawn for the use of thiazolidinediones in cancer therapy

  2014cites this paper
• Troglitazone and Δ2Troglitazone Enhance Adiponectin Expression in Monocytes/Macrophages through the AMP-Activated Protein Kinase Pathway

  2014cites this paper
• Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathway.

  2014cites this paper
• Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells

  2014cites this paper
• Supporting a Role for the GTPase Rab7 in Prostate Cancer Progression

  2014cites this paper
• The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism.

  2014cites this paper
• A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis.

  2014cites this paper
• Ciglitazone enhances ovarian cancer cell death via inhibition of glucose transporter-1.

  2014cites this paper
• WLIP derived from Lasiosphaera fenzlii Reich exhibits anti-tumor activity and induces cell cycle arrest through PPAR-γ associated pathways.

  2014cites this paper
• Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation.

  2014cites this paper
• Positive and negative effects of glitazones in carcinogenesis: experimental models vs. clinical practice.

  2014cites this paper
• Impact des ligands de PPARs, et leurs dérivés, sur les cellules cancéreuses coliques humaines : modifications des statuts redox et glycolytique

  2014cites this paper
• Synthesis and Antimicrobial Activity of Some New N-substituted-5-arylidene-thiazolidine-2,4-diones

  2014cites this paper
• Influence of 17β-estradiol on 15-deoxy-δ12,14 prostaglandin J2 -induced apoptosis in MCF-7 and MDA-MB-231 cells.

  2013cites this paper
• Metformin and cancer.

  2013cites this paper
• Rosiglitazone shows partial oncostatic effect in rat mammary carcinogenesis.

  2013cites this paper
• Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

  2013cites this paper
• Thiazolidine-2,4-diones: progress towards multifarious applications.

  2013cites this paper
• Thiazolidinediones protect mouse pancreatic β-cells directly from cytokine-induced cytotoxicity through PPARγ-dependent mechanisms

  2013cites this paper
• Antitumor effects of energy restriction-mimetic agents: thiazolidinediones

  2013cites this paper
• The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

  2013cites this paper
• Diabetes and Cancer

  2013cites this paper
• Adipocytes: impact on tumor growth and potential sites for therapeutic intervention.

  2013cites this paper
• Optimierung der Therapie des metastasierten Mammakarzinoms unter besonderer Berücksichtigung des Pi3K/Akt/mTOR-Signaltransduktionswegs

  2013cites this paper
• PPARα and PPARγ regulate the nucleoside transporter hENT1.

  2012cites this paper
• Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

  2012cites this paper
• The effect of metformin and thiazolidinedione use on lung cancer in diabetics

  2012cites this paper
• Effects of PPARγ Ligands on Leukemia

  2012cites this paper
• PPAR gamma, bioactive lipids, and cancer progression.

  2012cites this paper
• PPARγ-independent activity of thiazolidinediones: a promising mechanism of action for new anticancer drugs?

  2012cites this paper
• The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention

  2012cites this paper
• The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

  2012cites this paper
• The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipooxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target

  2012cites this paper
• New thiazolidine-2,4-diones as antimicrobial and cytotoxic agent

  2012cites this paper
• Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.

  2012cites this paper
• EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.

  2011cites this paper
• Human liposarcoma cell line SW872 as a research tool for differentiation, adipocytokine secretion and pharmacological regulation

  2011cites this paper
• Etude du facteur de transcription précoce EGR1 dans l'effet anti-prolifératif des ligands de PPARgamma sur les cellules cancéreuses mammaires

  2011cites this paper
• Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect.

  2011cites this paper
• Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

  2011cites this paper
• The Antidiabetic Drug Ciglitazone Induces High Grade Bladder Cancer Cells Apoptosis through the Up-Regulation of TRAIL

  2011cites this paper
• Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.

  2011cites this paper
• Pleiotropic Effects of Glitazones: A Double Edge Sword?

  2011cites this paper
• PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells

  2011cites this paper